Asian stocks mixed ahead of US inflation data - Asian stocks are mixed after Wall Street’s mostly positive performance ahead ...

Ozempic's patented semaglutide ingredient is also used in Novo's wildly popular obesity treatment Wegovy and diabetes tablets ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

The FDA has approved Zepbound, a popular weight loss drug, for the treatment of moderate-to-severe obstructive sleep apnea. According to drugmaker Eli Lilly, it’s the first and only FDA-approved ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

BCCI held a review meeting at their Mumbai headquarters to discuss India's 1-3 Test series defeat in Australia ... addressed issues like R Ashwin's mid-tour retirement and senior players' form.